PROVECTUS BIOPHARMACEUTICALS AND PEDIATRIC ONCOLOGY EXPERIMENTAL THERAPEUTICS INVESTIGATORS' CONSORTIUM (POETIC) ANNOUNCE ACCEPTANCE OF PV-10 POSTER PRESENTATION AT AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING
April 25, 2018 16:00 ET
|
Provectus Biopharmaceuticals Inc.
FOR IMMEDIATE RELEASE Preclinical pediatric cancer research undertaken at POETIC member institutions Alberta Children’s Hospital (Canada) and Memorial Sloan Kettering Cancer Center KNOXVILLE,...
PROVECTUS BIOPHARMACEUTICALS ANNOUNCES CHANGES TO BOARD OF DIRECTORS
April 24, 2018 07:00 ET
|
Provectus Biopharmaceuticals Inc.
FOR IMMEDIATE RELEASE Ed Pershing, CPA elected new Board chair Jack Lacey, MD named new Board director; also appointed new strategic advisory board chair KNOXVILLE, TN, April 24, 2018 ...
SECOND STUDY OF EXPANDED ACCESS PATIENTS TREATED WITH PV-10 FOR IN-TRANSIT MELANOMA PUBLISHED IN JOURNAL OF SURGICAL ONCOLOGY
April 19, 2018 06:00 ET
|
Provectus Biopharmaceuticals Inc.
FOR IMMEDIATE RELEASE KNOXVILLE, TN, April 19, 2018 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, www.provectusbio.com) (“Provectus” or the “Company”), a...
PROVECTUS BIOPHARMACEUTICALS EXPANDS GLOBAL PATENT PORTFOLIO FOR CANCER COMBINATION THERAPY
April 18, 2018 06:00 ET
|
Provectus Biopharmaceuticals Inc.
FOR IMMEDIATE RELEASE KNOXVILLE, TN, April 18, 2018 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, www.provectusbio.com) (“Provectus” or the “Company”), a clinical-stage...
PROVECTUS BIOPHARMACEUTICALS PROVIDES UPDATE ON GI CANCER PROGRAM FOR INVESTIGATIONAL DRUG PV-10
February 22, 2018 07:00 ET
|
Provectus Biopharmaceuticals Inc.
Current Phase 1 basket study continues to enroll and treat patients for HCC and liver cancer metastases (colorectal, lung, pancreatic, melanoma, ovarian, and breast); updated data presentation planned...
PROVECTUS BIOPHARMACEUTICALS RECEIVES THIRD CANCER COMBINATION THERAPY PATENT FROM THE UNITED STATES PATENT AND TRADEMARK OFFICE
December 14, 2017 06:00 ET
|
Provectus Biopharmaceuticals Inc.
– Protection expands coverage for combinations of intralesional PV-10 with checkpoint inhibitors for multiple solid tumor cancers – KNOXVILLE, TN, Dec. 14, 2017 (GLOBE NEWSWIRE) -- Provectus...